Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437535 | 0.83 | LMNA (0.35) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL18737326 | 0.80 | LMNA (0.34) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL13849297 | 0.78 | MMP1 (0.37) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL14200244 | 0.78 | ALDH1A1 (0.34) | LMNA | |
| SCHEMBL23475302 | 0.77 | — | — | |
| SCHEMBL23408410 | 0.77 | LMNA (0.41) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL10489425 | 0.77 | CA12 (0.48) | LMNACA12CA1CA9MMP1 | |
| SCHEMBL14982939 | 0.76 | NAMPT (0.32) | — | |
| SCHEMBL139066 | 0.75 | — | — | |
| SCHEMBL6244448 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10787592-B1 | Chemical mechanical polishing compositions and methods having enhanced defect inhibition and selectively polishing silicon nitride over silicon dioxide in an acid environment | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, I (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2017078332-A1 | METHOD FOR FORMING THREE-DIMENSIONAL OBJECT | 주식회사 엘지화학 | 2017-05-11 | — | — | WO | disclosed |
| WO-2017014538-A1 | INK COMPOSITION FOR 3D PRINTING SUPPORT AND 3D PRINTING MANUFACTURING METHOD USING SAME | 주식회사 엘지화학 | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 553/4885CA12 3259/4885CA1 2927/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | LMNA 553/4885CA12 3259/4885CA1 2927/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | LMNA 553/4885CA12 3259/4885CA1 2927/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | LMNA 553/4885CA12 3259/4885CA1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.